BioCryst Pharmaceuticals (BCRX) Financials

$7.96 +0.14 (+1.73%)

Closing price 04/23/2025 03:59 PM Eastern

Extended Trading

$7.96 0.00 (0.00%)

As of 04/23/2025 04:20 PM Eastern

Annual Income Statements for BioCryst Pharmaceuticals

This table shows BioCryst Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-45	-43	-55	-66	-101	-109	-183	-184	-247	-225	-89
Consolidated Net Income / (Loss)	-45	-43	-55	-66	-101	-109	-183	-184	-247	-227	-89
Net Income / (Loss) Continuing Operations	-45	-43	-55	-66	-101	-109	-183	-184	-247	-227	-89
Total Pre-Tax Income	-45	-43	-55	-66	-101	-109	-183	-182	-244	-226	-87
Total Operating Income	-46	-39	-49	-57	-94	-99	-175	-178	-148	-104	-2.54
Total Gross Profit	14	47	24	24	21	45	16	150	264	327	438
Total Revenue	14	48	26	25	21	49	18	157	271	331	451
Operating Revenue	14	48	26	25	21	49	18	157	271	331	451
Total Cost of Revenue	0.00	1.37	2.30	1.14	0.00	3.73	1.55	7.23	6.41	4.48	12
Operating Cost of Revenue	0.00	1.37	2.30	1.14	0.00	3.73	1.55	7.23	6.41	4.48	12
Total Operating Expenses	59	86	73	81	115	145	191	328	413	431	441
Selling, General & Admin Expense	7.46	13	11	14	30	37	68	119	159	214	266
Research & Development Expense	52	73	61	67	85	107	123	209	253	217	175
Other Operating Expenses / (Income)	0.12	0.53	0.40	0.56	0.47	0.38	0.13	0.04	0.19	0.18	0.22
Total Other Income / (Expense), net	0.58	-3.58	-6.54	-8.37	-7.03	-9.44	-8.06	-4.09	-96	-123	-84
Interest Expense	5.00	5.20	6.49	8.57	6.92	9.96	7.09	3.46	99	137	99
Interest & Investment Income	5.58	1.63	-0.05	0.19	-	0.52	-0.97	-0.63	3.14	15	14
Income Tax Expense	-	-	-	-	-	0.00	0.00	2.25	2.73	0.31	1.93
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.13	0.08	-0.19	0.23	-	-0.34	0.04	-0.17	-0.89	-0.18	0.78
Basic Earnings per Share	($0.68)	($0.59)	($0.75)	($0.78)	($0.98)	($940.00)	($1.09)	($1.03)	($1.33)	($1.18)	($0.43)
Weighted Average Basic Shares Outstanding	66.77M	73M	73.30M	84.60M	103.40M	154.19M	167.27M	179.12M	185.91M	192.20M	206.70M
Diluted Earnings per Share	($0.68)	($0.59)	($0.75)	($0.78)	($0.98)	($940.00)	($1.09)	($1.03)	($1.33)	($1.18)	($0.43)
Weighted Average Diluted Shares Outstanding	66.77M	72.90M	73.70M	84.45M	103.19M	115.60M	167.27M	179.12M	185.91M	192.20M	206.70M
Weighted Average Basic & Diluted Shares Outstanding	66.77M	73M	73.30M	84.60M	103.40M	154.19M	177.18M	184.66M	188.45M	206.15M	208.96M

This table shows BioCryst Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-43	-71	-53	-75	-36	-61	-36	-13	-12	-28
Consolidated Net Income / (Loss)	-43	-72	-53	-75	-36	-62	-35	-13	-14	-27
Net Income / (Loss) Continuing Operations	-43	-72	-53	-75	-36	-62	-35	-13	-14	-27
Total Pre-Tax Income	-41	-71	-53	-75	-36	-63	-35	-13	-13	-26
Total Operating Income	-17	-46	-28	-21	-12	-43	-14	8.76	7.69	-4.51
Total Gross Profit	72	77	68	82	86	92	91	108	114	125
Total Revenue	76	80	69	82	87	93	93	109	117	132
Operating Revenue	76	80	69	82	87	93	93	109	117	132
Total Cost of Revenue	3.54	2.38	0.93	0.89	1.10	1.56	1.27	1.70	3.21	6.09
Operating Cost of Revenue	3.54	2.38	0.93	0.89	1.10	1.56	1.27	1.70	3.21	6.09
Total Operating Expenses	90	123	96	102	98	135	106	99	106	130
Selling, General & Admin Expense	37	50	48	51	51	64	59	61	65	80
Research & Development Expense	53	73	48	51	47	70	46	38	41	49
Other Operating Expenses / (Income)	0.07	0.11	0.01	0.06	0.04	0.08	0.13	0.04	0.02	0.04
Total Other Income / (Expense), net	-24	-25	-24	-54	-24	-20	-21	-21	-21	-21
Interest Expense	25	26	27	58	27	25	25	25	25	24
Interest & Investment Income	1.22	1.30	3.15	4.05	3.45	4.09	3.98	3.47	3.69	2.97
Income Tax Expense	1.52	0.08	0.67	0.74	0.33	-1.43	0.37	0.17	0.59	0.80
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.11	-1.17	-0.56	-0.11	-0.11	0.59	0.57	0.21	-1.74	1.73
Basic Earnings per Share	($0.23)	($0.38)	($0.28)	($0.40)	($0.19)	($0.31)	($0.17)	($0.06)	($0.07)	($0.13)
Weighted Average Basic Shares Outstanding	186.18M	185.91M	188.51M	189.12M	189.64M	192.20M	206.06M	206.43M	206.91M	206.70M
Diluted Earnings per Share	($0.23)	($0.38)	($0.28)	($0.40)	($0.19)	($0.31)	($0.17)	($0.06)	($0.07)	($0.13)
Weighted Average Diluted Shares Outstanding	186.18M	185.91M	188.51M	189.12M	189.64M	192.20M	206.06M	206.43M	206.91M	206.70M
Weighted Average Basic & Diluted Shares Outstanding	186.42M	188.45M	188.93M	189.49M	204.81M	206.15M	206.38M	206.89M	207.13M	208.96M

This table details how cash moves in and out of BioCryst Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	33	-26	-6.86	30	-25	87	159	233	-201	-194	-6.12
Net Cash From Operating Activities	-39	-13	-53	-41	-93	-90	-135	-142	-162	-95	-52
Net Cash From Continuing Operating Activities	-39	-13	-53	-41	-93	-90	-135	-142	-162	-95	-52
Net Income / (Loss) Continuing Operations	-45	-43	-55	-66	-101	-109	-183	-184	-247	-227	-89
Consolidated Net Income / (Loss)	-45	-43	-55	-66	-101	-109	-183	-184	-247	-227	-89
Depreciation Expense	0.18	0.18	0.48	0.70	0.77	0.72	0.75	0.78	1.44	1.66	1.25
Amortization Expense	0.59	1.01	1.08	1.03	1.00	1.40	3.45	54	97	76	56
Non-Cash Adjustments To Reconcile Net Income	10	9.71	8.50	13	9.40	18	16	-21	46	87	67
Changes in Operating Assets and Liabilities, net	-4.33	19	-8.36	10	-2.48	-0.53	28	8.12	-59	-32	-87
Net Cash From Investing Activities	-40	-18	23	-65	4.77	78	-6.86	16	-128	-131	53
Net Cash From Continuing Investing Activities	-40	-18	23	-65	4.77	78	-6.86	16	-128	-131	53
Purchase of Property, Plant & Equipment	-0.11	-5.12	-5.28	-0.33	-0.37	-0.34	-0.51	-2.39	-1.35	-2.17	-1.12
Purchase of Investments	-74	-54	-14	-108	-63	-3.02	-50	-10	-244	-514	-267
Sale and/or Maturity of Investments	34	42	43	43	68	81	43	28	117	385	320
Net Cash From Financing Activities	112	5.48	23	136	63	99	301	360	88	32	-5.76
Net Cash From Continuing Financing Activities	112	5.48	23	136	63	99	301	360	88	32	-5.76
Repayment of Debt	0.00	0.00	0.00	0.00	-4.03	0.00	-52	0.00	0.00	-273	0.00
Issuance of Debt	-	-	23	0.00	10	19	120	0.00	73	300	0.00
Issuance of Common Equity	107	0.00	0.00	134	53	78	108	66	15	8.34	3.44
Other Financing Activities, net	5.31	5.48	0.65	1.70	2.78	1.24	125	294	0.19	-3.00	-9.21
Effect of Exchange Rate Changes	-	-	-	-	-	0.00	-	0.07	0.57	0.36	-0.94
Cash Interest Paid	-	-	-	-	-	-	-	0.90	0.00	22	30
Cash Income Taxes Paid	-	-	-	-	-	-	-	0.12	3.54	1.43	1.60

This table details how cash moves in and out of BioCryst Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-26	58	-150	-8.81	4.70	-40	-26	-5.93	19	7.26
Net Cash From Operating Activities	-32	-24	-48	-19	-20	-8.92	-54	-1.37	8.25	-5.21
Net Cash From Continuing Operating Activities	-32	-24	-48	-19	-20	-8.92	-54	-1.37	8.25	-5.21
Net Income / (Loss) Continuing Operations	-43	-72	-53	-75	-36	-62	-35	-13	-14	-27
Consolidated Net Income / (Loss)	-43	-72	-53	-75	-36	-62	-35	-13	-14	-27
Depreciation Expense	0.39	0.40	0.41	0.41	0.42	0.42	0.31	0.32	0.31	0.31
Amortization Expense	18	43	19	21	20	16	16	16	12	11
Non-Cash Adjustments To Reconcile Net Income	9.95	16	14	42	12	18	14	13	19	21
Changes in Operating Assets and Liabilities, net	-18	-12	-28	-6.64	-16	18	-49	-18	-9.13	-11
Net Cash From Investing Activities	-70	77	-107	-19	23	-28	29	-2.45	8.49	18
Net Cash From Continuing Investing Activities	-70	77	-107	-19	23	-28	29	-2.45	8.49	18
Purchase of Property, Plant & Equipment	-0.18	-0.53	-0.16	-0.47	-0.99	-0.55	-0.24	-0.16	-0.06	-0.68
Purchase of Investments	-105	-	-149	-85	-124	-157	-88	-112	-27	-40
Sale and/or Maturity of Investments	36	78	42	66	148	129	117	110	35	58
Net Cash From Financing Activities	76	4.20	5.08	29	1.23	-3.17	-1.05	-1.97	1.27	-4.02
Net Cash From Continuing Financing Activities	76	4.20	5.08	29	1.23	-3.17	-1.05	-1.97	1.27	-4.02
Issuance of Common Equity	-	-	5.08	1.75	1.48	0.04	1.68	0.26	2.09	-0.59
Other Financing Activities, net	3.25	-11	0.00	0.21	0.01	-3.21	-2.73	-2.23	-0.81	-3.44
Effect of Exchange Rate Changes	-0.01	0.33	-0.10	-0.32	0.25	0.52	-0.34	-0.14	0.85	-1.30
Cash Interest Paid	-	-	7.14	5.16	4.85	4.99	4.99	5.05	10	10
Cash Income Taxes Paid	-	-	0.14	0.98	0.32	-0.01	0.19	0.68	0.36	0.38

This table presents BioCryst Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	137	122	90	178	147	175	335	588	550	517	490
Total Current Assets	89	64	67	125	114	164	324	566	517	496	422
Cash & Equivalents	55	29	22	50	27	114	272	504	305	111	105
Restricted Cash	0.15	1.61	1.55	3.29	1.54	1.55	2.22	3.35	1.47	1.80	0.21
Short-Term Investments	18	23	33	64	78	22	28	3.21	120	278	216
Accounts Receivable	9.49	6.24	8.77	6.12	4.29	22	8.65	29	51	57	79
Inventories, net	0.68	1.61	0.50	0.00	1.65	0.00	7.04	16	28	29	8.09
Prepaid Expenses	6.17	2.67	1.44	1.38	2.40	4.42	5.53	9.99	13	20	14
Plant, Property, & Equipment, net	0.21	5.15	9.92	9.55	-	7.35	7.11	8.71	8.62	7.91	7.78
Total Noncurrent Assets	47	53	13	43	-	3.59	3.80	13	25	13	61
Long-Term Investments	41	48	8.93	41	22	-	0.00	6.83	18	0.00	20
Other Noncurrent Operating Assets	6.21	5.73	4.01	2.03	0.98	3.59	3.80	6.47	6.81	13	40
Total Liabilities & Shareholders' Equity	137	122	90	178	147	175	335	588	550	517	490
Total Liabilities	61	75	88	94	-	137	354	695	845	972	966
Total Current Liabilities	57	62	54	75	69	92	106	104	106	150	160
Accounts Payable	2.85	9.31	4.27	6.34	7.77	14	19	28	14	21	12
Accrued Expenses	11	16	11	13	16	21	34	73	88	103	113
Other Current Liabilities	-	-	-	-	-	1.38	1.18	1.82	2.37	26	35
Total Noncurrent Liabilities	3.95	12	34	20	-	45	248	591	739	823	806
Long-Term Debt	-	0.00	23	17	25	41	120	136	232	303	315
Other Noncurrent Operating Liabilities	-	-	-	-	2.70	0.00	129	455	507	519	491
Total Equity & Noncontrolling Interests	76	48	1.58	84	-	38	-19	-107	-295	-456	-476
Total Preferred & Common Equity	76	48	1.58	84	-	38	-19	-107	-295	-456	-476
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	76	48	1.58	84	-	38	-19	-107	-295	-456	-476
Common Stock	544	559	568	716	782	879	1,004	1,100	1,160	1,224	1,293
Retained Earnings	-468	-511	-566	-632	-732	-841	-1,023	-1,208	-1,455	-1,681	-1,770
Accumulated Other Comprehensive Income / (Loss)	-0.13	-0.21	-0.01	-0.24	-0.30	0.04	0.00	0.18	0.03	1.34	0.92

This table presents BioCryst Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	559	510	530	523	468	472	491
Total Current Assets	509	491	511	502	447	363	427
Cash & Equivalents	247	155	146	151	84	78	97
Restricted Cash	1.44	1.46	1.57	1.58	1.80	1.80	0.81
Short-Term Investments	180	243	264	247	252	194	233
Accounts Receivable	43	49	58	54	61	69	72
Inventories, net	27	27	27	30	30	4.45	7.56
Prepaid Expenses	11	15	14	20	18	16	16
Plant, Property, & Equipment, net	8.46	8.38	8.44	9.00	7.83	7.66	7.42
Total Noncurrent Assets	41	10	10	11	13	101	57
Long-Term Investments	34	3.43	3.45	0.00	-	64	19
Other Noncurrent Operating Assets	6.80	7.05	6.95	11	13	37	37
Total Liabilities & Shareholders' Equity	559	510	530	523	468	472	491
Total Liabilities	801	838	919	934	944	948	960
Total Current Liabilities	82	85	93	91	120	129	154
Accounts Payable	8.62	6.25	14	11	12	7.79	13
Accrued Expenses	69	75	75	77	79	90	104
Other Current Liabilities	2.20	2.49	2.53	2.28	29	32	36
Total Noncurrent Liabilities	720	753	825	843	824	819	806
Long-Term Debt	224	233	293	298	308	314	314
Other Noncurrent Operating Liabilities	490	514	526	535	516	505	492
Total Equity & Noncontrolling Interests	-243	-328	-389	-411	-476	-476	-469
Total Preferred & Common Equity	-243	-328	-389	-411	-476	-476	-469
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-243	-328	-389	-411	-476	-476	-469
Common Stock	1,141	1,179	1,194	1,208	1,240	1,253	1,272
Retained Earnings	-1,383	-1,508	-1,583	-1,619	-1,717	-1,729	-1,743
Accumulated Other Comprehensive Income / (Loss)	-0.10	0.59	0.69	0.80	0.77	0.56	2.29

This table displays calculated financial ratios and metrics derived from BioCryst Pharmaceuticals' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-21.48%	254.62%	-45.39%	-4.43%	-18.00%	136.45%	-63.53%	782.38%	72.31%	22.37%	36.00%
EBITDA Growth	-349.00%	15.00%	-22.97%	-18.35%	-66.26%	-5.16%	-75.23%	28.04%	59.38%	46.82%	306.82%
EBIT Growth	-364.10%	13.82%	-23.23%	-18.11%	-64.30%	-5.44%	-75.71%	-1.70%	16.48%	30.13%	97.55%
NOPAT Growth	-284.87%	13.82%	-23.23%	-18.11%	-64.11%	-5.56%	-75.71%	-1.70%	16.48%	30.13%	97.55%
Net Income Growth	-50.09%	4.80%	-28.19%	-19.29%	-53.92%	-7.55%	-67.88%	-0.68%	-34.26%	8.33%	60.77%
EPS Growth	0.00%	13.24%	-27.12%	-4.00%	-25.64%	-95,818.37%	99.88%	5.50%	-29.13%	11.28%	63.56%
Operating Cash Flow Growth	-45.31%	65.98%	-307.43%	23.01%	-124.98%	3.22%	-50.82%	-5.22%	-13.85%	41.22%	45.32%
Free Cash Flow Firm Growth	-289.85%	63.47%	-258.63%	33.97%	-102.67%	-15.71%	134.99%	698.80%	-140.10%	57.62%	-16.73%
Invested Capital Growth	70.50%	-582.77%	94.88%	-911.33%	1.94%	83.66%	-11,085.43%	-224.82%	-3.71%	-7.15%	7.48%
Revenue Q/Q Growth	0.00%	-1.72%	19.94%	-16.82%	-5.32%	312.49%	-66.72%	37.83%	13.58%	4.36%	9.24%
EBITDA Q/Q Growth	-483.61%	-5.73%	16.30%	-20.99%	-8.91%	20.71%	-42.04%	11.32%	38.49%	-677.54%	154.10%
EBIT Q/Q Growth	-512.39%	-5.45%	15.63%	-20.26%	-8.65%	20.19%	-42.70%	0.13%	3.80%	3.39%	93.75%
NOPAT Q/Q Growth	-512.39%	-5.45%	15.63%	-20.26%	-8.52%	20.19%	-42.70%	0.13%	3.80%	3.39%	93.75%
Net Income Q/Q Growth	-16.03%	-17.68%	19.82%	-29.64%	-8.45%	18.56%	-46.32%	18.84%	-27.81%	4.15%	28.22%
EPS Q/Q Growth	-11.48%	-15.69%	19.35%	-21.88%	-5.38%	-77,585.95%	99.92%	-100.21%	-26.67%	5.60%	29.51%
Operating Cash Flow Q/Q Growth	-32.13%	-7.70%	14.38%	-12.79%	-17.02%	13.13%	-31.14%	6.62%	5.05%	13.56%	6.65%
Free Cash Flow Firm Q/Q Growth	-484.81%	-193.83%	43.11%	3.07%	-13.58%	-13.38%	127.97%	1,088.45%	-141.00%	24.92%	-61.84%
Invested Capital Q/Q Growth	74.50%	67.69%	77.38%	-144.94%	-37.46%	94.77%	-855.62%	-208.71%	-6.60%	-8.14%	0.40%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	99.99%	97.17%	91.28%	95.47%	100.00%	92.37%	91.30%	95.40%	97.63%	98.65%	97.28%
EBITDA Margin	-330.72%	-79.27%	-178.51%	-221.05%	-448.18%	-199.32%	-957.57%	-78.09%	-18.41%	-8.00%	12.17%
Operating Margin	-336.35%	-81.74%	-184.45%	-227.95%	-456.20%	-203.66%	-981.12%	-113.08%	-54.81%	-31.29%	-0.56%
EBIT Margin	-336.35%	-81.74%	-184.45%	-227.95%	-456.73%	-203.66%	-981.12%	-113.08%	-54.81%	-31.29%	-0.56%
Profit (Net Income) Margin	-332.08%	-89.15%	-209.25%	-261.18%	-490.25%	-222.99%	-1,026.35%	-117.11%	-91.25%	-68.36%	-19.72%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	101.24%	101.12%	100.14%	102.22%
Interest Burden Percent	98.73%	109.06%	113.45%	114.58%	107.34%	109.49%	104.61%	102.30%	164.64%	218.14%	3,419.35%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-121.30%	-69.75%	-223.70%	-154.16%	-152.26%	-248.94%	-1,925.37%	291.59%	123.07%	60.40%	19.08%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-49.29%	-30.43%	-45.81%	-42.83%	-58.03%	-61.75%	-68.53%	-38.51%	-26.08%	-19.44%	-0.50%
Return on Assets (ROA)	-48.66%	-33.19%	-51.97%	-49.07%	-62.29%	-67.61%	-71.69%	-39.89%	-43.42%	-42.46%	-17.65%
Return on Common Equity (ROCE)	-121.30%	-69.75%	-223.70%	-154.16%	-152.26%	-248.94%	-1,925.37%	291.59%	123.07%	60.40%	19.08%
Return on Equity Simple (ROE_SIMPLE)	-59.75%	-90.14%	-3,494.55%	-78.53%	-205.65%	-284.68%	949.09%	172.04%	83.88%	49.73%	18.68%
Net Operating Profit after Tax (NOPAT)	-32	-28	-34	-40	-66	-70	-122	-124	-104	-73	-1.78
NOPAT Margin	-235.45%	-57.22%	-129.11%	-159.56%	-319.34%	-142.56%	-686.78%	-79.15%	-38.37%	-21.91%	-0.40%
Net Nonoperating Expense Percent (NNEP)	-30.97%	-21.71%	-63.67%	-54.13%	-47.18%	-80.93%	-70.83%	-23.26%	-48.23%	-102.70%	-152.71%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	165.00%	47.67%	1.11%
Cost of Revenue to Revenue	0.01%	2.83%	8.72%	4.53%	0.00%	7.63%	8.70%	4.60%	2.37%	1.35%	2.72%
SG&A Expenses to Revenue	54.83%	27.04%	42.70%	55.32%	142.90%	76.01%	381.37%	75.60%	58.85%	64.54%	59.05%
R&D to Revenue	380.63%	150.77%	231.50%	265.87%	411.02%	219.24%	690.34%	132.85%	93.53%	65.35%	38.75%
Operating Expenses to Revenue	436.35%	178.90%	275.73%	323.41%	556.20%	296.03%	1,072.42%	208.48%	152.44%	129.94%	97.84%
Earnings before Interest and Taxes (EBIT)	-46	-39	-49	-57	-94	-99	-175	-178	-148	-104	-2.54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-45	-38	-47	-56	-93	-97	-171	-123	-50	-27	55
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	15.86	295.87	5.77	17.97	9.96	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	15.86	295.87	5.77	17.97	9.96	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	15.68	17.72	19.18	42.84	7.80	73.85	15.86	7.90	3.70	3.46
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	14.22	17.28	15.04	39.49	6.69	65.27	13.43	7.12	3.44	3.40
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	27.92
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	43.43	9.87	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.40	0.63	34.05	0.65	1.20	2.18	-7.77	-1.27	-0.79	-0.67	-0.66
Long-Term Debt to Equity	0.00	0.05	16.15	0.23	0.52	1.17	-6.22	-1.27	-0.79	-0.67	-0.66
Financial Leverage	-1.14	-1.15	-1.35	-1.11	-1.13	-1.11	-8.99	4.06	1.48	0.40	0.12
Leverage Ratio	2.49	2.10	4.30	3.14	2.44	3.68	26.86	-7.31	-2.83	-1.42	-1.08
Compound Leverage Factor	2.46	2.29	4.88	3.60	2.62	4.03	28.09	-7.48	-4.67	-3.10	-36.98
Debt to Total Capital	28.40%	38.74%	97.15%	39.51%	54.54%	68.52%	114.76%	467.70%	-367.81%	-199.11%	-195.49%
Short-Term Debt to Total Capital	28.40%	35.69%	51.07%	25.43%	31.12%	31.75%	22.99%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	3.05%	46.08%	14.08%	23.43%	36.78%	91.77%	467.70%	-367.81%	-199.11%	-195.49%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	71.60%	61.26%	2.85%	60.49%	45.46%	31.48%	-14.76%	-367.70%	467.81%	299.11%	295.49%
Debt to EBITDA	-0.67	-0.79	-1.14	-0.98	-0.64	-0.86	-0.88	-1.11	-4.65	-11.44	5.74
Net Debt to EBITDA	1.87	1.85	0.24	1.87	0.75	0.56	0.90	3.11	4.26	3.30	-0.48
Long-Term Debt to EBITDA	0.00	-0.06	-0.54	-0.35	-0.27	-0.46	-0.70	-1.11	-4.65	-11.44	5.74
Debt to NOPAT	-0.94	-1.09	-1.58	-1.36	-0.90	-1.20	-1.22	-1.09	-2.23	-4.18	-176.88
Net Debt to NOPAT	2.62	2.56	0.34	2.59	1.05	0.78	1.25	3.07	2.04	1.21	14.89
Long-Term Debt to NOPAT	0.00	-0.09	-0.75	-0.49	-0.38	-0.64	-0.98	-1.09	-2.23	-4.18	-176.88
Altman Z-Score	0.00	-0.42	-6.97	-2.48	-3.15	-6.15	-2.94	-0.51	-1.68	-3.01	-2.54
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.56	1.02	1.23	1.68	1.65	1.78	3.06	5.46	4.90	3.31	2.63
Quick Ratio	1.44	0.93	1.17	1.61	1.57	1.72	2.92	5.18	4.50	2.97	2.49
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-38	-14	-49	-33	-66	-77	27	214	-86	-36	-42
Operating Cash Flow to CapEx	-36,368.87%	-256.07%	-1,012.66%	-13,019.94%	-25,290.98%	-26,117.78%	-26,285.60%	-5,960.46%	-11,980.01%	-4,388.42%	-4,628.11%
Free Cash Flow to Firm to Interest Expense	-7.55	-2.65	-7.62	-3.81	-9.55	-7.68	3.77	61.87	-0.87	-0.26	-0.43
Operating Cash Flow to Interest Expense	-7.71	-2.52	-8.24	-4.80	-13.37	-9.00	-19.05	-41.13	-1.63	-0.69	-0.53
Operating Cash Flow Less CapEx to Interest Expense	-7.73	-3.51	-9.05	-4.84	-13.42	-9.03	-19.12	-41.82	-1.65	-0.71	-0.54
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.15	0.37	0.25	0.19	0.13	0.30	0.07	0.34	0.48	0.62	0.89
Accounts Receivable Turnover	2.35	6.13	3.51	3.38	3.97	3.69	1.16	8.26	6.77	6.16	6.63
Inventory Turnover	0.00	1.19	2.18	0.00	0.00	0.00	0.00	0.63	0.30	0.16	0.67
Fixed Asset Turnover	53.05	18.02	3.50	2.59	2.21	5.93	2.46	19.86	31.25	40.11	57.46
Accounts Payable Turnover	0.00	0.23	0.34	0.22	0.00	0.34	0.09	0.31	0.30	0.25	0.75
Days Sales Outstanding (DSO)	155.64	59.50	103.95	107.86	91.99	98.80	315.49	44.19	53.92	59.22	55.08
Days Inventory Outstanding (DIO)	0.00	306.17	167.80	0.00	0.00	0.00	0.00	576.36	1,233.87	2,289.54	546.95
Days Payable Outstanding (DPO)	1,281,697.50	1,621.69	1,078.63	1,694.92	0.00	1,065.66	3,850.28	1,174.45	1,200.83	1,435.60	483.98
Cash Conversion Cycle (CCC)	-1,281,541.86	-1,256.02	-806.88	-1,587.06	91.99	-966.86	-3,534.79	-553.90	86.95	913.16	118.04
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-2.37	-16	-0.83	-8.39	-8.23	-1.35	-150	-489	-507	-543	-502
Invested Capital Turnover	-2.61	-5.19	-3.09	-5.46	-2.48	-10.20	-0.23	-0.49	-0.54	-0.63	-0.86
Increase / (Decrease) in Invested Capital	5.67	-14	15	-7.56	0.16	6.89	-149	-338	-18	-36	41
Enterprise Value (EV)	0.00	686	455	379	815	327	1,163	2,110	1,928	1,139	1,531
Market Capitalization	0.00	757	467	483	885	381	1,315	2,492	2,140	1,227	1,558
Book Value per Share	$1.13	$0.65	$0.02	$0.85	$0.45	$0.35	($0.11)	($0.59)	($1.58)	($2.22)	($2.30)
Tangible Book Value per Share	$1.13	$0.65	$0.02	$0.85	$0.45	$0.35	($0.11)	($0.59)	($1.58)	($2.22)	($2.30)
Total Capital	106	78	55	138	108	122	130	29	-63	-152	-161
Total Debt	30	30	54	55	59	83	150	136	232	303	315
Total Long-Term Debt	0.00	2.38	25	20	25	45	120	136	232	303	315
Net Debt	-84	-71	-11	-104	-69	-55	-153	-382	-212	-88	-27
Capital Expenditures (CapEx)	0.11	5.12	5.28	0.32	0.37	0.34	0.51	2.39	1.35	2.17	1.12
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-11	-24	-15	-32	-27	-27	-54	-49	-15	-45	-59
Debt-free Net Working Capital (DFNWC)	62	29	41	86	79	111	248	462	411	346	262
Net Working Capital (NWC)	32	1.54	13	51	45	72	218	462	411	346	262
Net Nonoperating Expense (NNE)	13	15	21	26	35	39	60	60	143	154	87
Net Nonoperating Obligations (NNO)	-78	-64	-2.41	-92	-57	-40	-131	-382	-212	-88	-27
Total Depreciation and Amortization (D&A)	0.77	1.19	1.56	1.74	1.77	2.12	4.19	55	99	77	57
Debt-free, Cash-free Net Working Capital to Revenue	-79.89%	-49.39%	-58.16%	-126.69%	-132.84%	-55.67%	-305.64%	-30.88%	-5.46%	-13.52%	-13.20%
Debt-free Net Working Capital to Revenue	455.98%	60.80%	155.09%	340.57%	380.46%	226.46%	1,393.14%	294.22%	151.75%	104.40%	58.04%
Net Working Capital to Revenue	235.52%	3.19%	47.91%	200.73%	217.28%	147.46%	1,224.71%	294.22%	151.75%	104.40%	58.04%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.68)	$0.00	($0.75)	($0.78)	($0.98)	($0.94)	($1.09)	($1,030.00)	($1.33)	($1.18)	($0.43)
Adjusted Weighted Average Basic Shares Outstanding	72.32M	73.58M	73.96M	98.61M	110.18M	154.19M	177.18M	184.66M	185.91M	192.20M	206.70M
Adjusted Diluted Earnings per Share	($0.68)	$0.00	($0.75)	($0.78)	($0.98)	($0.94)	($1.09)	($1,030.00)	($1.33)	($1.18)	($0.43)
Adjusted Weighted Average Diluted Shares Outstanding	72.32M	73.58M	73.70M	84.45M	103.19M	115.60M	167.27M	179.12M	185.91M	192.20M	206.70M
Adjusted Basic & Diluted Earnings per Share	($0.68)	($0.59)	($0.75)	($0.78)	($0.98)	($0.94)	($1.09)	($1,030.00)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	66.77M	73.58M	73.96M	98.61M	110.18M	154.19M	177.18M	184.66M	188.45M	206.15M	208.96M
Normalized Net Operating Profit after Tax (NOPAT)	-32	-28	-34	-40	-66	-70	-122	-124	-104	-73	-1.78
Normalized NOPAT Margin	-235.45%	-57.22%	-129.11%	-159.56%	-319.34%	-142.56%	-686.78%	-79.15%	-38.37%	-21.91%	-0.40%
Pre Tax Income Margin	-332.08%	-89.15%	-209.25%	-261.18%	-490.25%	-222.99%	-1,026.35%	-115.68%	-90.24%	-68.26%	-19.29%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-9.16	-7.59	-7.49	-6.70	-13.62	-9.99	-24.64	-51.42	-1.50	-0.76	-0.03
NOPAT to Interest Expense	-6.41	-5.31	-5.25	-4.69	-9.53	-6.99	-17.25	-36.00	-1.05	-0.53	-0.02
EBIT Less CapEx to Interest Expense	-9.18	-8.57	-8.31	-6.74	-13.68	-10.02	-24.71	-52.11	-1.51	-0.77	-0.04
NOPAT Less CapEx to Interest Expense	-6.43	-6.29	-6.06	-4.73	-9.58	-7.03	-17.32	-36.69	-1.06	-0.54	-0.03
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from BioCryst Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	84.97%	68.68%	37.77%	25.88%	14.39%	17.42%	34.87%	32.54%	34.98%	40.83%
EBITDA Growth	101.99%	91.03%	70.01%	103.52%	1,257.40%	-751.35%	122.63%	4,162.10%	148.32%	127.03%
EBIT Growth	60.87%	11.24%	43.12%	40.38%	31.67%	7.86%	49.01%	142.32%	164.52%	89.44%
NOPAT Growth	60.87%	11.24%	43.12%	40.38%	31.67%	7.86%	49.01%	142.32%	164.52%	89.44%
Net Income Growth	27.69%	-302.39%	28.12%	-27.98%	14.98%	13.71%	33.66%	83.17%	61.18%	56.59%
EPS Growth	30.30%	-280.00%	30.00%	-25.00%	17.39%	18.42%	39.29%	85.00%	63.16%	58.06%
Operating Cash Flow Growth	-39.39%	26.53%	38.93%	32.22%	38.67%	62.61%	-12.99%	92.73%	141.44%	41.55%
Free Cash Flow Firm Growth	173.87%	-104.73%	-99.26%	-96.98%	-93.97%	144.77%	37.26%	-93.33%	-58.32%	-785.70%
Invested Capital Growth	-200.35%	-3.71%	-4.69%	-4.98%	-5.62%	-7.15%	-2.67%	1.09%	-0.45%	7.48%
Revenue Q/Q Growth	15.71%	4.90%	-13.54%	19.94%	5.15%	7.68%	-0.69%	17.86%	7.09%	12.34%
EBITDA Q/Q Growth	103.62%	-605.76%	-198.50%	106.44%	1,296.45%	-417.21%	107.93%	1,112.76%	-18.64%	-65.47%
EBIT Q/Q Growth	49.76%	-165.47%	38.64%	27.14%	42.42%	-257.94%	66.05%	160.47%	-12.20%	-158.61%
NOPAT Q/Q Growth	49.76%	-165.47%	38.64%	27.14%	42.42%	-257.94%	66.05%	160.47%	-12.20%	-158.61%
Net Income Q/Q Growth	27.76%	-68.25%	25.45%	-41.24%	52.01%	-70.77%	42.69%	64.18%	-10.72%	-90.94%
EPS Q/Q Growth	28.13%	-65.22%	26.32%	-42.86%	52.50%	-63.16%	45.16%	64.71%	-16.67%	-85.71%
Operating Cash Flow Q/Q Growth	-16.89%	26.49%	-99.22%	60.40%	-5.76%	55.18%	-501.97%	97.45%	702.70%	-163.23%
Free Cash Flow Firm Q/Q Growth	-3.01%	-104.68%	115.37%	332.47%	94.01%	-65.28%	-15.04%	-78.98%	1,111.85%	-671.19%
Invested Capital Q/Q Growth	1.24%	-6.60%	2.75%	-2.54%	0.64%	-8.14%	6.33%	1.21%	-0.91%	0.40%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	95.33%	97.00%	98.65%	98.92%	98.73%	98.33%	98.64%	98.45%	97.26%	95.37%
EBITDA Margin	0.80%	-3.87%	-13.35%	0.72%	9.51%	-28.03%	2.24%	23.04%	17.50%	5.38%
Operating Margin	-23.01%	-58.22%	-41.31%	-25.10%	-13.74%	-45.68%	-15.62%	8.01%	6.57%	-3.43%
EBIT Margin	-23.01%	-58.22%	-41.31%	-25.10%	-13.74%	-45.68%	-15.62%	8.01%	6.57%	-3.43%
Profit (Net Income) Margin	-56.08%	-89.94%	-77.54%	-91.31%	-41.67%	-66.09%	-38.14%	-11.59%	-11.99%	-20.37%
Tax Burden Percent	103.71%	100.11%	101.27%	100.99%	100.92%	97.73%	101.04%	101.38%	104.36%	103.09%
Interest Burden Percent	235.01%	154.32%	185.33%	360.27%	300.47%	148.02%	241.68%	-142.70%	-174.82%	576.55%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	99.23%	123.07%	91.88%	80.65%	72.32%	60.40%	51.86%	33.77%	28.15%	19.08%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-13.31%	-27.71%	-23.07%	-14.79%	-8.07%	-28.38%	-11.36%	6.11%	5.35%	-3.07%
Return on Assets (ROA)	-32.44%	-42.80%	-43.30%	-53.83%	-24.47%	-41.06%	-27.73%	-8.84%	-9.75%	-18.23%
Return on Common Equity (ROCE)	99.23%	123.07%	91.88%	80.65%	72.32%	60.40%	51.86%	33.77%	28.15%	19.08%
Return on Equity Simple (ROE_SIMPLE)	79.68%	0.00%	68.92%	62.44%	57.51%	0.00%	43.81%	30.68%	26.42%	0.00%
Net Operating Profit after Tax (NOPAT)	-12	-32	-20	-14	-8.34	-30	-10	6.13	5.38	-3.16
NOPAT Margin	-16.10%	-40.75%	-28.92%	-17.57%	-9.62%	-31.98%	-10.93%	5.61%	4.60%	-2.40%
Net Nonoperating Expense Percent (NNEP)	-24.84%	-13.17%	-14.20%	-31.61%	-17.16%	-21.26%	-25.96%	-26.67%	-30.55%	-41.45%
Return On Investment Capital (ROIC_SIMPLE)	-	51.48%	-	-	-	19.61%	-	-	-	1.96%
Cost of Revenue to Revenue	4.67%	3.00%	1.35%	1.08%	1.27%	1.67%	1.36%	1.55%	2.74%	4.63%
SG&A Expenses to Revenue	48.69%	63.05%	69.60%	61.82%	58.39%	68.93%	64.00%	55.99%	55.59%	61.18%
R&D to Revenue	69.55%	92.03%	70.35%	62.12%	54.04%	75.00%	50.12%	34.41%	35.09%	37.59%
Operating Expenses to Revenue	118.33%	155.22%	139.96%	124.01%	112.48%	144.02%	114.25%	90.43%	90.69%	98.79%
Earnings before Interest and Taxes (EBIT)	-17	-46	-28	-21	-12	-43	-14	8.76	7.69	-4.51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	0.61	-3.08	-9.18	0.59	8.25	-26	2.08	25	20	7.08
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	9.83	7.90	5.43	4.34	4.22	3.70	2.93	3.34	3.81	3.46
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	8.85	7.12	4.86	3.96	3.94	3.44	2.84	3.27	3.72	3.40
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	133.95	71.19	27.92
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	10.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-0.95	-0.79	-0.73	-0.77	-0.75	-0.67	-0.65	-0.66	-0.67	-0.66
Long-Term Debt to Equity	-0.95	-0.79	-0.73	-0.77	-0.75	-0.67	-0.65	-0.66	-0.67	-0.66
Financial Leverage	0.63	1.48	0.96	0.64	0.50	0.40	0.24	0.16	0.14	0.12
Leverage Ratio	-2.12	-2.83	-2.11	-1.73	-1.65	-1.42	-1.22	-1.16	-1.15	-1.08
Compound Leverage Factor	-4.97	-4.37	-3.90	-6.23	-4.97	-2.11	-2.94	1.65	2.02	-6.24
Debt to Total Capital	-1,792.23%	-367.81%	-265.45%	-333.18%	-298.92%	-199.11%	-183.97%	-193.98%	-203.81%	-195.49%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	-1,792.23%	-367.81%	-265.45%	-333.18%	-298.92%	-199.11%	-183.97%	-193.98%	-203.81%	-195.49%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	1,892.23%	467.81%	365.45%	433.18%	398.92%	299.11%	283.97%	293.98%	303.81%	295.49%
Debt to EBITDA	-2.84	-4.65	-8.39	-27.04	-90.31	-11.44	-20.22	33.60	14.57	5.74
Net Debt to EBITDA	2.87	4.26	5.79	10.56	26.75	3.30	1.96	-2.60	-1.66	-0.48
Long-Term Debt to EBITDA	-2.84	-4.65	-8.39	-27.04	-90.31	-11.44	-20.22	33.60	14.57	5.74
Debt to NOPAT	-2.13	-2.23	-2.68	-3.78	-4.10	-4.18	-4.91	-7.43	-11.03	-176.88
Net Debt to NOPAT	2.16	2.04	1.85	1.48	1.21	1.21	0.48	0.58	1.26	14.89
Long-Term Debt to NOPAT	-2.13	-2.23	-2.68	-3.78	-4.10	-4.18	-4.91	-7.43	-11.03	-176.88
Altman Z-Score	-0.47	-1.07	-1.68	-1.92	-2.00	-2.62	-2.98	-2.85	-2.43	-2.56
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.23	4.90	5.76	5.47	5.54	3.31	3.73	2.82	2.78	2.63
Quick Ratio	5.75	4.50	5.25	5.01	4.97	2.97	3.31	2.64	2.62	2.49
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	305	-14	2.19	9.48	18	6.39	3.01	0.63	7.67	-44
Operating Cash Flow to CapEx	-18,539.43%	-4,534.03%	-29,695.00%	-4,028.69%	-2,015.91%	-1,609.75%	-22,844.26%	-882.58%	13,974.58%	-772.30%
Free Cash Flow to Firm to Interest Expense	12.31	-0.54	0.08	0.16	0.67	0.26	0.12	0.03	0.31	-1.79
Operating Cash Flow to Interest Expense	-1.31	-0.90	-1.73	-0.32	-0.73	-0.36	-2.19	-0.06	0.33	-0.21
Operating Cash Flow Less CapEx to Interest Expense	-1.32	-0.92	-1.74	-0.33	-0.76	-0.39	-2.20	-0.06	0.33	-0.24
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.58	0.48	0.56	0.59	0.59	0.62	0.73	0.76	0.81	0.89
Accounts Receivable Turnover	6.93	6.77	6.81	6.18	6.60	6.16	6.51	6.05	6.54	6.63
Inventory Turnover	0.22	0.30	0.33	0.31	0.19	0.16	0.17	0.36	0.42	0.67
Fixed Asset Turnover	29.27	31.25	33.73	35.78	36.37	40.11	43.86	47.48	50.25	57.46
Accounts Payable Turnover	0.31	0.30	0.71	0.60	0.55	0.25	0.53	0.52	0.64	0.75
Days Sales Outstanding (DSO)	52.68	53.92	53.58	59.01	55.32	59.22	56.09	60.36	55.78	55.08
Days Inventory Outstanding (DIO)	1,671.05	1,233.87	1,120.49	1,186.94	1,948.08	2,289.54	2,169.80	1,022.36	877.85	546.95
Days Payable Outstanding (DPO)	1,163.06	1,200.83	517.34	610.13	659.88	1,435.60	688.46	703.86	567.63	483.98
Cash Conversion Cycle (CCC)	560.66	86.95	656.74	635.83	1,343.51	913.16	1,537.43	378.86	366.00	118.04
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-475	-507	-493	-505	-502	-543	-506	-500	-504	-502
Invested Capital Turnover	-0.75	-0.54	-0.60	-0.62	-0.65	-0.63	-0.71	-0.76	-0.82	-0.86
Increase / (Decrease) in Invested Capital	-317	-18	-22	-24	-27	-36	-13	5.50	-2.28	41
Enterprise Value (EV)	2,110	1,928	1,407	1,213	1,250	1,139	1,011	1,251	1,536	1,531
Market Capitalization	2,343	2,140	1,572	1,330	1,342	1,227	1,040	1,275	1,572	1,558
Book Value per Share	($1.31)	($1.58)	($1.74)	($2.06)	($2.17)	($2.22)	($2.31)	($2.30)	($2.26)	($2.30)
Tangible Book Value per Share	($1.31)	($1.58)	($1.74)	($2.06)	($2.17)	($2.22)	($2.31)	($2.30)	($2.26)	($2.30)
Total Capital	-13	-63	-90	-90	-103	-152	-168	-162	-154	-161
Total Debt	230	232	238	299	308	303	308	314	314	315
Total Long-Term Debt	230	232	238	299	308	303	308	314	314	315
Net Debt	-233	-212	-165	-117	-91	-88	-30	-24	-36	-27
Capital Expenditures (CapEx)	0.18	0.53	0.16	0.47	0.99	0.55	0.24	0.16	0.06	0.68
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.94	-15	6.11	5.31	13	-45	-11	-39	-57	-59
Debt-free Net Working Capital (DFNWC)	427	411	406	418	412	346	327	234	274	262
Net Working Capital (NWC)	427	411	406	418	412	346	327	234	274	262
Net Nonoperating Expense (NNE)	30	39	33	61	28	32	25	19	19	24
Net Nonoperating Obligations (NNO)	-233	-212	-165	-117	-91	-88	-30	-24	-36	-27
Total Depreciation and Amortization (D&A)	18	43	19	21	20	16	17	16	13	12
Debt-free, Cash-free Net Working Capital to Revenue	-0.39%	-5.46%	2.11%	1.73%	3.95%	-13.52%	-3.14%	-10.32%	-13.88%	-13.20%
Debt-free Net Working Capital to Revenue	179.23%	151.75%	140.06%	136.17%	129.65%	104.40%	92.06%	61.32%	66.30%	58.04%
Net Working Capital to Revenue	179.23%	151.75%	140.06%	136.17%	129.65%	104.40%	92.06%	61.32%	66.30%	58.04%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.23)	($0.38)	($0.28)	($0.40)	($0.19)	($0.31)	($0.17)	($0.06)	($0.07)	($0.13)
Adjusted Weighted Average Basic Shares Outstanding	186.18M	185.91M	188.51M	189.12M	189.64M	192.20M	206.06M	206.43M	206.91M	206.70M
Adjusted Diluted Earnings per Share	($0.23)	($0.38)	($0.28)	($0.40)	($0.19)	($0.31)	($0.17)	($0.06)	($0.07)	($0.13)
Adjusted Weighted Average Diluted Shares Outstanding	186.18M	185.91M	188.51M	189.12M	189.64M	192.20M	206.06M	206.43M	206.91M	206.70M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	186.42M	188.45M	188.93M	189.49M	204.81M	206.15M	206.38M	206.89M	207.13M	208.96M
Normalized Net Operating Profit after Tax (NOPAT)	-12	-32	-20	-14	-8.34	-30	-10	6.13	5.38	-3.16
Normalized NOPAT Margin	-16.10%	-40.75%	-28.92%	-17.57%	-9.62%	-31.98%	-10.93%	5.61%	4.60%	-2.40%
Pre Tax Income Margin	-54.07%	-89.84%	-76.57%	-90.42%	-41.29%	-67.62%	-37.75%	-11.43%	-11.48%	-19.76%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-0.70	-1.75	-1.04	-0.36	-0.44	-1.74	-0.59	0.35	0.31	-0.18
NOPAT to Interest Expense	-0.49	-1.23	-0.73	-0.25	-0.31	-1.22	-0.41	0.25	0.22	-0.13
EBIT Less CapEx to Interest Expense	-0.71	-1.77	-1.04	-0.37	-0.47	-1.76	-0.60	0.35	0.31	-0.21
NOPAT Less CapEx to Interest Expense	-0.50	-1.25	-0.73	-0.26	-0.34	-1.24	-0.42	0.24	0.21	-0.16
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About BioCryst Pharmaceuticals' Financials

When does BioCryst Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, BioCryst Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has BioCryst Pharmaceuticals' net income changed over the last 10 years?

BioCryst Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$88.88 million in 2024, rising from -$45.19 million in 2014. The previous period was -$226.54 million in 2023.

What is BioCryst Pharmaceuticals's operating income?

BioCryst Pharmaceuticals's total operating income in 2024 was -$2.54 million, based on the following breakdown:

Total Gross Profit: $438.44 million
Total Operating Expenses: $440.99 million

How has BioCryst Pharmaceuticals revenue changed over the last 10 years?

Over the last 10 years, BioCryst Pharmaceuticals' total revenue changed from $13.61 million in 2014 to $450.71 million in 2024, a change of 3,212.1%.

How much debt does BioCryst Pharmaceuticals have?

BioCryst Pharmaceuticals' total liabilities were at $966.35 million at the end of 2024, a 0.6% decrease from 2023, and a 1,478.0% increase since 2014.

How much cash does BioCryst Pharmaceuticals have?

In the past 10 years, BioCryst Pharmaceuticals' cash and equivalents has ranged from $22.10 million in 2016 to $504.39 million in 2021, and is currently $104.71 million as of their latest financial filing in 2024.

How has BioCryst Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, BioCryst Pharmaceuticals' book value per share changed from 1.13 in 2014 to -2.30 in 2024, a change of -302.9%.

Related Companies

This page (NASDAQ:BCRX) was last updated on 4/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCryst Pharmaceuticals (BCRX) Financials

Frequently Asked Questions About BioCryst Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCryst Pharmaceuticals (BCRX) Financials

Annual Income Statements for BioCryst Pharmaceuticals

Quarterly Income Statements for BioCryst Pharmaceuticals

Annual Cash Flow Statements for BioCryst Pharmaceuticals

Quarterly Cash Flow Statements for BioCryst Pharmaceuticals

Annual Balance Sheets for BioCryst Pharmaceuticals

Quarterly Balance Sheets for BioCryst Pharmaceuticals

Annual Metrics and Ratios for BioCryst Pharmaceuticals

Quarterly Metrics and Ratios for BioCryst Pharmaceuticals

Frequently Asked Questions About BioCryst Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools